Evidence map›Paper›PMID 33526632›Full record

ArticleStroke and vascular neurology2021

Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors.

Mark R Etherton, Shreyansh Shah, Xu Haolin, Ying Xian, Lesley Maisch, Deidre Hannah, Brianna Lindholm, Barbara Lytle, Laine Thomas, Eric E Smith and 5 more

Abstract read
In one paragraph

Article in Stroke and vascular neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Post-stroke Everything.Current neurology and neuroscience reports · 2023
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mark R EthertonNeurology, Massachusetts General Hospital, Boston, Massachusetts, USA metherton@partners.org.ORCID 0000-0002-4739-2449
Shreyansh ShahNeurology, Duke University School of Medicine, Durham, North Carolina, USA.ORCID 0000-0001-8441-6326
Xu HaolinDuke Clinical Research Institute, Duke University, Durham, North Carolina, USA.ORCID 0000-0003-1069-9567
Ying XianNeurology, Duke University School of Medicine, Durham, North Carolina, USA.
Lesley MaischAmerican Heart Association Inc, Dallas, Texas, USA.
Deidre HannahAmerican Heart Association Inc, Dallas, Texas, USA.
Brianna LindholmAmerican Heart Association Inc, Dallas, Texas, USA.
Barbara LytleDuke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
Laine ThomasDuke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
Eric E SmithClinical Neurosciences, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
Gregg C FonarowCardiology, Ronald Reagan UCLA Medical Center, Los Angeles, California, USA.
Lee H SchwammNeurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Deepak L BhattCardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Adrian F HernandezCardiology, Duke University, Durham, North Carolina, USA.
Emily C O'BrienPopulation Health, Duke Clinical Research Institute, Durham, North Carolina, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeDepression is common after stroke and is often treated with antidepressant medications (AD). ADs have also been hypothesised to improve stroke recovery, although recent randomised trials were neutral. We investigated the patterns of in-hospital AD initiation after ischaemic stroke and association with clinical and readmission outcomes.

methodsAll Medicare fee-for-service beneficiaries aged 65 or older hospitalised for ischaemic stroke in participating Get With The Guidelines-Stroke hospitals between April and December 2014 were eligible for this analysis. Outcome measures included days alive and not in a healthcare institution (home time), all-cause mortality and readmission within 1-year postdischarge. Propensity score (PS)-adjusted logistic regression models were used to evaluate the associations between AD use and each outcome measure. We also compared outcomes in patients prescribed selective serotonin reuptake inhibitors (SSRIs) AD versus those prescribed non-SSRI ADs.

resultsOf 21 805 AD naïve patients included in this analysis, 1835 (8.4%) were started on an AD at discharge. Patients started on an AD had higher rates of depression and prior ischaemic stroke, presented with higher admission National Institutes of Health Stroke Scale score and were less likely to be discharged home. Similarly, patients started on an SSRI had lower rates of discharge to home. Adjusting for stroke severity, patients started on an AD had worse all-cause mortality, all-cause readmission, major adverse cardiac events, readmission for depression and decreased home-time. However, AD use was also associated with an increased risk for the sepsis, a falsification endpoint, suggesting the presence of residual confounding.

conclusionsPatients with ischaemic stroke initiated on AD therapy are at increased risk of poor clinical outcomes and readmission even after PS adjustment, suggesting that poststroke depression requiring medication is a poor prognostic sign. Further research is needed to explore the reasons why depression is associated with worse outcome, and whether AD treatment modifies this risk or not.

Indexed as

Brain IschemiaIschemic StrokeStrokeAftercareAgedAntidepressive AgentsHumansMedicarePatient DischargeSurvivorsUnited StatesAntidepressive Agentsstroke

Identifiers

PMID33526632
PMCPMC8485250

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.